MedImmune, Inc.
News and overview for MedImmune, Inc.
Harte-Hanks and MedImmune Win Medical Marketing & Media Gold Award [Press Release]
MarketWire | 6 days 13 hours 27 minutes ago
SAN ANTONIO, TX -- (Marketwire) -- 11/18/09 --
Zyngenia, Inc. Raises $10 Million in Series A Funding [Press Release]
PRNewswire | 20 days 8 hours 12 minutes ago
...D., former head of MedImmune Ventures, Inc., as Chief Business Officer. Dr. Amprey joined MedImmune Ventures as the first...During his 16 years at MedImmune, it grew from a small...Pharmaceuticals and Trevena, Inc. He trained in Internal...
CBI Announces Keynote Panel Discussion on Learning from the Pharma Meeting Planner at Upcoming Conference on Evolving Hotel Sale Strategies for Hotels Targeting the Life Science Industry [Press Release]
PRNewswire | 36 days 16 hours 37 minutes ago
BOSTON, Oct. 19 /PRNewswire/ -- The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to announce the full program agenda for
Vaccine for swine flu scores a success
Philadelphia Inquirer, The | 10 days 51 minutes ago
Of the companies that make the vaccine for the swine flu, only one has avoided the production problems caused by a slow-growing virus strain.
Research and Markets: Opportunity Analysis of H1N1 (swine flu) Vaccination Market - The Global H1N1 Influenza Vaccine Market is Estimated to be of 676 Million in 2009 [Press Release]
Business Wire | 1 day 21 hours 12 minutes ago
Research and Markets (http://www.researchandmarkets.com/research/18be8b/opportunity_analys) has announced the addition of the "Opportunity Analysis of H1N1 (swine flu) Vaccination Market" report to their offering.
Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors [Press Release]
PRNewswire | 69 days 21 hours 9 minutes ago
Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors PRNewswire...Rib-X Pharmaceuticals, Inc., a company focused on the... Mr. Zook is President of MedImmune, Chief Executive Officer of...
CBI Hosts 5th Annual Pharma/Biotech Enterprise Governance, Risk and Controls Congress [Press Release]
PRNewswire | 98 days 21 hours 10 minutes ago
...Myers Squibb -- Cephalon -- Eisai Pharmaceuticals -- Elan Pharmaceuticals, Inc. -- GlaxoSmithKline -- MedImmune, Inc. -- Par Pharmaceutical Companies Inc. -- sanofi-aventis Pharmaceuticals -- Shire Pharmaceutical This prestigious...
Micromet buys remaining rights to cancer fighting drug
American City Business Journals | 19 days 13 hours 55 minutes ago
Micromet says it has bought out MedImmune Inc.’s stake in cancer-fighting protein blinatumomab, giving it rights to commercialize the drug in North America.
MedImmune to present 4 abstracts on RSV and influenza at 47TH Annual IDSA Meeting
EurekAlert! | 25 days 16 hours 43 minutes ago
MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America being held here Oct. 29-Nov. 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus and influenza prevention, highlighting MedImmune's leadership in pediatric health.
Americans Urged To Get Seasonal Influenza Vaccine Early [Press Release]
PRNewswire | 75 days 19 hours 9 minutes ago
...educational grants to NFID from CSL Biotherapies, Inc., Flu Vaccine Business Practices Initiative (c/o HIDA), GlaxoSmithKline, MedImmune, Merck and Co., Inc., Novartis Vaccines, Roche, sanofi pasteur and...
'Golden era' could bring vaccines against AIDS, Alzheimer's and addictions within 5 years -- South Florida Sun-Sentinel.com
Sun-Sentinel (Fort Lauderdale, Fla.) | 6 days 18 hours 3 minutes ago
MARIETTA, Pa. (AP) — Malaria . Tuberculosis . Alzheimer's disease . AIDS . Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.
FDA Approves Vaccines for 2009 H1N1 Influenza Virus [Press Release]
PRNewswire | 70 days 13 hours 10 minutes ago
...serious illness and death from influenza." The vaccines are made by CSL Limited, MedImmune LLC, Novartis Vaccines and Diagnostics Limited, and sanofi pasteur Inc. All four firms manufacture the H1N1 vaccines using the same processes, which have...
Blumenthal Investigating Possible Vaccine Price Gouging
Hartford Courant (Conn.), The | 21 days 21 hours 58 minutes ago
Doctors, nursing agencies and other health care providers have reported to state regulators that the price of seasonal flu vaccine has shot up to as much $100 a dose in some cases, triggering an investigation by Attorney General Richard Blumenthal into possible price gouging.
Zyngenia raises $10M from New Enterprise Associates
American City Business Journals | 20 days 12 hours 47 minutes ago
Former MedImmune executives have left to launch a new biotech company, Zyngenia Inc.
Sanofi says it'll deliver on flu vaccine
Philadelphia Inquirer, The | 13 days 51 minutes ago
SWIFTWATER, Pa. - Sanofi-Aventis Group, under pressure with other vaccine-makers to meet intense public demand for flu vaccine in the United States, yesterday said it solved problems that had slowed production and was working around-the-clock to deliver the 75 million doses of H1N1 vaccine it promised the federal government by the end of December.
Sign up for BIO SmartBrief
Company Overview
| Company: | MedImmune, Inc. |
|---|---|
| Industry: | Biopharmaceuticals & Biotherapeutics |
| Website: | http://www.medimmune.com |
MedImmune works to boost the immune systems of babies and grown-ups. Its flagship biotech product, Synagis, prevents respiratory syncytial virus (RSV), a major cause of pneumonia and other respiratory disease in infants and children. Also on the market are FluMist, its nasal spray flu vaccine, and Ethyol, which treats side effects of chemotherapy and radiation. The company is working on dozens of investigational therapies -- including monoclonal antibodies, vaccines, and small molecule drugs -- in the areas of infectious diseases, cancer, and inflammatory conditions. MedImmune is a subsidiary of UK-based pharmaceutical giant AstraZeneca.
Key Numbers
| Sales in U.S. Dollars (mil.) | 0 () |
|---|---|
| One-year % Growth in Sales | 0.0 () |
| Net Income in U.S. Dollars (mil.) | 0 () |
| One-year % Growth in Net Income | 0.0 () |
| Number of Employees | 0 (0) |
| One-year % Growth in Number of Employees | 0.0 (0) |
| Fiscal Year-End |